Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13881MR)

This product GTTS-WQ13881MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13881MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3114MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ5213MR IVTScrip™ mRNA-Anti-CD22, CAT-8015(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAT-8015
GTTS-WQ9474MR IVTScrip™ mRNA-Anti-C5AR1, IPH-5401(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IPH-5401
GTTS-WQ13293MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA PF-06523435
GTTS-WQ14643MR IVTScrip™ mRNA-Anti-DLL3, SC0001-SCX(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SC0001-SCX
GTTS-WQ843MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ABBV-155
GTTS-WQ9348MR IVTScrip™ mRNA-Anti-PDCD1, INCMGA-00012(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA INCMGA-00012
GTTS-WQ6747MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA DS 992
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW